Psoriasis during interferon beta treatment for multiple sclerosis.
Previous reports have suggested an increased risk of psoriasis in MS patients. Worsening of dermatologic lesions during interferon therapy has been rarely reported, but activation of psoriatic arthritis has not been described until now. The following is a case report. A 37-year-old woman affected by relapsing-remitting multiple sclerosis had severe worsening of cutaneous psoriasis and activation of psoriatic arthritis during interferon beta treatment. The symptoms resolved after therapy discontinuation. This case further supports that activation of psoriasis might be a rare side effect of IFNB therapy and suggests careful evaluation of concomitant morbidity to allow a patient-oriented treatment strategy.
La Mantia
Loredana
L
Multiple Sclerosis Center, Neurological Institute C Besta, Via Celoria, 11, 20133, Milan, Italy. lamantia@istituto-besta.it
Capsoni
F
F
D000328:Adult; D015535:Arthritis, Psoriatic / Q000139:chemically induced / Q000150:complications / Q000473:pathology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use*; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011565:Psoriasis / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D012720:Severity of Illness Index
D007155:Immunologic Factors; D016899:Interferon-beta